Literature DB >> 30339198

Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.

Y C Zhu1, W X Wang2, C W Xu3, Q X Zhang4, K Q Du1, G Chen4, T F Lv5, Y Song5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30339198     DOI： 10.1093/annonc/mdy455

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

1.  Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.

Authors:  Félix Blanc-Durand; Raafat Alameddine; Anthony J Iafrate; Danh Tran-Thanh; Ying-Chun Lo; Normand Blais; Bertrand Routy; Mustapha Tehfé; Charles Leduc; Phillipe Romeo; Phillipe Stephenson; Marie Florescu
Journal:  Oncologist       Date:  2020-09-08

Review 2.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

3.  Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.

Authors:  Yiyi Yu; Qing Liu; Wei Li; Yueting Qu; Yihong Zhang; Tianshu Liu
Journal:  Oncologist       Date:  2020-10-12

Review 4.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 5.  A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.

Authors:  Mariacarmela Santarpia; Marco Massafra; Vittorio Gebbia; Antonio D'Aquino; Claudia Garipoli; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2021-03

6.  Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion.

Authors:  Qing Ma; Lingping Kong; Diansheng Zhong
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

7.  Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report.

Authors:  Lian-Fang Liu; Jia-Ying Deng; Analyn Lizaso; Jing Lin; Si Sun
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

8.  Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion.

Authors:  Lanzi Ou; Yicong Tang; Yanming Deng; Lijie Guo; Qingqing He; Tingting He; Weineng Feng
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

9.  Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin.

Authors:  Chien-Yu Lin; Sheng-Huan Wei; Yi-Lin Chen; Chung-Ta Lee; Shang-Yin Wu; Chung-Liang Ho; Dean C Pavlick; Po-Lan Su; Chien-Chung Lin
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

10.  Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report.

Authors:  Junfang Liu; Lijun Shen; Yunyao Qian; Yunpeng Liu; Minhong Su; Li Yi
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.